{"id":618761,"date":"2022-09-28T14:28:01","date_gmt":"2022-09-28T14:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=618761"},"modified":"2022-09-28T14:28:01","modified_gmt":"2022-09-28T14:28:01","slug":"adc-cytotoxic-payloads-warheads-market-is-anticipated-to-grow-at-a-cagr-of-124-till-2030-roots-analysis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/adc-cytotoxic-payloads-warheads-market-is-anticipated-to-grow-at-a-cagr-of-124-till-2030-roots-analysis_618761.html","title":{"rendered":"ADC Cytotoxic Payloads \/ Warheads market is anticipated to grow at a CAGR of 12.4% till 2030 | Roots Analysis"},"content":{"rendered":"
Roots Analysis has announced the addition of \u201cADC Cytotoxic Payloads \/ Warheads: Products and Services Market, 2021-2030\u201d report to its list of offerings.<\/div>\n

With six approved drugs, namely POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA®, ADCETRIS® and over 300 drugs underdevelopment, antibody drug conjugates (ADCs) have emerged as a promising class of targeted therapies for various disease indications<\/strong><\/p>\n

Roots Analysis has announced the addition of “ADC Cytotoxic Payloads \/ Warheads: Products and Services Market, 2021-2030<\/strong><\/a>” report to its list of offerings.  <\/p>\n

Given the fact that ADCs are highly potent cytotoxic molecules, the manufacturing of ADCs requires elaborate and advanced technical capabilities and highly potent chemical substances. Specifically, the multi-step process of production of cytotoxic payloads, which are complex structures used in ADCs, requires a specially designed and contained environment, dedicated manufacturing facilities, specialized analytical and purification techniques, and storage facilities.   <\/p>\n

Key Market Insights<\/strong><\/p>\n

Over 40 companies claim to offer ADC cytotoxic payloads \/ warheads for ADCs<\/strong><\/p>\n

Presently, the market is dominated by the presence of large (501-10,000 employees) and mid-sized companies ( 51-500 employees). It is worth noting that majority (44%) of the firms engaged in this domain are based in Europe, followed by North America (28%) and Asia Pacific (28%).<\/p>\n

More than 430 patents related to ADC cytotoxic payloads \/ warheads have been granted \/ filed between 2016-2021<\/strong><\/p>\n

A significant increase has been observed in the number of patent applications filed over the last few years. Majority (80%) of the patents were filed \/ granted in North America; other key regions with significant intellectual capital include regions of Europe and South Korea<\/p>\n

Close to 40 partnerships have been inked among various industry and non-industry players between 2016 and 2021<\/strong><\/p>\n

Maximum number of partnerships were established in 2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that, majority of the deals were licensing agreements, representing over 35% of the total number of partnerships signed in the given time period.<\/p>\n

Close to USD 1,100 million has been invested by both private and public investors, since 2016<\/strong><\/p>\n

Of the total amount invested, over USD 719 million was raised through venture capital financing, representing over 42% of the overall funding activity in this domain. Further, 5 instances of private placements were also reported, wherein players collectively raised more than USD 190 million.<\/p>\n

North America and Europe are anticipated to capture larger share of the market share by 2030<\/strong><\/p>\n

Growth in this domain is anticipated to be primarily driven by the demand of auristatins and maytansinoids payloads. It is worth mentioning that ADC cytotoxic payloads \/ warheads market for microtubule inhibitors is likely to capture nearly 40% of the total market share by 2030.   <\/p>\n

Request for Customization @ <\/strong>https:\/\/www.rootsanalysis.com\/reports\/adc-cytotoxic-payloads-market\/request-customization.html<\/strong><\/a><\/p>\n

Key Questions Answered<\/strong><\/p>\n